Document Detail


Microparticle-associated tissue factor activity and venous thrombosis in multiple myeloma.
MedLine Citation:
PMID:  21057704     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
Multiple myeloma (MM) is associated with an increased risk of venous thromboembolic (VTE) complications. Aim of this study was to measure microparticle-associated tissue factor (MP-TF) activity in patients with newly diagnosed MM before and after chemotherapy and to investigate whether MP-TF activity is associated with VTE. MP-TF activity was assessed in 122 newly diagnosed MM patients who were eligible for combination chemotherapy. MP-TF activity levels (17.6 fM Xa/min [8.6-33.2] (median [IQR]) were higher in untreated MM patients compared to normal healthy volunteers (4.1 fM Xa/min [2.3-6.6], p <0.001). MP-TF activity prior to the start of treatment was not different between patients who developed a VTE during follow-up (n=15) and those who did not (n=107). In 75 patients in whom plasma was obtained before and after chemotherapy, MP-TF activity decreased significantly (from 17.4 [10.2-32.8] to 12.0 [7.0-18.5] fM Xa/min, P=0.006). MP-TF activity remained, however, elevated in patients who developed VTE (15.1 [10.3-25.2]), in contrast to patients not developing VTE (11.4 [7.0-25.2], P<0.001). In conclusion, MP-TF activity is increased in patients with MM. Whether MP-TF activity has a pathogenetic role in VTE in MM patients remains to be established in future studies.
Authors:
Johannes J A Auwerda; Yuana Yuana; Susanne Osanto; Moniek P M de Maat; Pieter Sonneveld; Rogier M Bertina; Frank W G Leebeek
Related Documents :
6464624 - Acute intestinal ischemia. a 14-year retrospective investigation.
10759014 - Risk of major bleeding in unselected patients with venous thromboembolism.
11835114 - Critical appraisal of the diagnostics of 270 consecutive cases of suspected venous thro...
20173134 - Migrating azygos vein and vanishing azygos lobe: mdct findings.
8437024 - Presence of t-cell subset abnormalities in newly diagnosed cases of multiple sclerosis ...
19367244 - Impact of reduced endogenous anti-coagulation protein activity on vascular events of pe...
Publication Detail:
Type:  Journal Article; Randomized Controlled Trial     Date:  2010-11-05
Journal Detail:
Title:  Thrombosis and haemostasis     Volume:  105     ISSN:  0340-6245     ISO Abbreviation:  Thromb. Haemost.     Publication Date:  2011 Jan 
Date Detail:
Created Date:  2011-01-04     Completed Date:  2011-05-18     Revised Date:  2011-05-23    
Medline Journal Info:
Nlm Unique ID:  7608063     Medline TA:  Thromb Haemost     Country:  Germany    
Other Details:
Languages:  eng     Pagination:  14-20     Citation Subset:  IM    
Affiliation:
Erasmus University Medical Center, Department of Hematology, Rotterdam, The Netherlands.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Adult
Aged
Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
Boronic Acids / therapeutic use
Case-Control Studies
Cell-Derived Microparticles / chemistry*
Dexamethasone / therapeutic use
Doxorubicin / therapeutic use
Female
Humans
Male
Middle Aged
Multiple Myeloma / chemistry,  complications*
Pyrazines / therapeutic use
Thalidomide / therapeutic use
Thromboplastin / analysis,  metabolism*
Venous Thrombosis / etiology*
Vincristine / therapeutic use
Chemical
Reg. No./Substance:
0/Boronic Acids; 0/Pyrazines; 0/bortezomib; 23214-92-8/Doxorubicin; 50-02-2/Dexamethasone; 50-35-1/Thalidomide; 57-22-7/Vincristine; 9035-58-9/Thromboplastin

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Impact of pharmacokinetic (CYP2C9) and pharmacodynamic (VKORC1, F7, GGCX, CALU, EPHX1) gene variants...
Next Document:  ADAMTS13 activity is decreased in a septic porcine model. Significance for glomerular thrombus depos...